Peter J. Fromen

Chief Executive Officer at Biomodal Ltd.

49 year

Health Technology

Consumer Services

Commercial Services

Profile

Peter J.
Fromen holds the position of Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
and Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
In the past he occupied the position of Senior Director-Investor Relations at Illumina, Inc. and Chief Commercial Officer at Pacific Biosciences of California, Inc. Peter J.
Fromen received an undergraduate degree from Kenyon College and an MBA from W.P.
Carey School of Business.

Peter J. Fromen active positions

Companies	Position	Start
Biomodal Ltd. Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.	Chief Executive Officer	2022-07-17

All active positions of Peter J. Fromen

Former positions of Peter J. Fromen

Companies	Position	End
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	Corporate Officer/Principal	2022-05-19
ILLUMINA, INC.	Investor Relations Contact	-

See the detail of Peter J. Fromen's experience

Training of Peter J. Fromen

Kenyon College	Undergraduate Degree
W.P. Carey School of Business	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter J. Fromen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ILLUMINA, INC.	Health Technology
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	Health Technology

Private companies	1
Biomodal Ltd. Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.	Commercial Services